GlassScriptPhysician profile
Swati K Gupta
NPI 1760467351
$3,475.52
in general payments reported to CMS, 2019-2025
28 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $271 · 2021: $832 · 2022: $1,005 · 2023: $518 · 2024: $439 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $666.74 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.44 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $373.52 | 2020-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $372.44 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $243.69 | 2020-2024 | Xarelto |
| Amgen INC. | $220.76 | 2020-2023 | Repatha |
| Novo Nordisk INC | $176.98 | 2020-2025 | Wegovy, Ozempic |
| Medtronic, INC. | $133.50 | 2021 | |
| Abiomed | $115.87 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $111.28 | 2020-2023 | Livalo |
| E.R. Squibb & Sons, L.L.C. | $97.41 | 2020-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $89.52 | 2019-2023 | Farxiga |
| Edwards Lifesciences Corporation | $68.20 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Erbe USA INC | $54.93 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $42.08 | 2024 | Arcalyst |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $38.24 | 2022-2023 | |
| Medicure Pharma INC. | $36.76 | 2021 | |
| Amarin Pharma, INC. | $36.11 | 2020-2021 | |
| Abbott Laboratories | $31.42 | 2022 | |
| Tactile Systems Technology INC | $27.80 | 2019 | |
| Scpharmaceuticals INC. | $25.23 | 2025 | |
| Lilly USA, LLC | $23.31 | 2023 | Mounjaro |
| Actelion Pharmaceuticals US, INC. | $21.58 | 2024 | Opsumit, Uptravi |
| Baxter Healthcare | $21.45 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $21.39 | 2020 | |
| Boston Scientific Corporation | $21.19 | 2021 | |
| Medtronic Vascular, INC. | $17.37 | 2020 | |
| Preventice Services, LLC | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.